Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.

Journal

Hepatology (Baltimore, Md.)

ISSN: 1527-3350

Titre abrégé: Hepatology

Pays: United States

ID NLM: 8302946

Informations de publication

Date de publication:
02 2021

Historique:

received: 21 04 2020

revised: 19 10 2020

accepted: 26 10 2020

pubmed: 11 11 2020

medline: 10 8 2021

entrez: 10 11 2020

Statut: ppublish

Résumé

Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or firsocostat 20 mg, alone or in two-drug combinations, once-daily for 48 weeks. The primary endpoint was a ≥1-stage improvement in fibrosis without worsening of NASH between baseline and 48 weeks based on central pathologist review. Exploratory endpoints included changes in NAFLD Activity Score (NAS), liver histology assessed using a machine learning (ML) approach, liver biochemistry, and noninvasive markers. The majority had cirrhosis (56%) and NAS ≥5 (83%). The primary endpoint was achieved in 11% of placebo-treated patients versus cilofexor/firsocostat (21%; P = 0.17), cilofexor/selonsertib (19%; P = 0.26), firsocostat/selonsertib (15%; P = 0.62), firsocostat (12%; P = 0.94), and cilofexor (12%; P = 0.96). Changes in hepatic collagen by morphometry were not significant, but cilofexor/firsocostat led to a significant decrease in ML NASH CRN fibrosis score (P = 0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns. Compared to placebo, significantly higher proportions of cilofexor/firsocostat patients had a ≥2-point NAS reduction; reductions in steatosis, lobular inflammation, and ballooning; and significant improvements in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, bile acids, cytokeratin-18, insulin, estimated glomerular filtration rate, ELF score, and liver stiffness by transient elastography (all P ≤ 0.05). Pruritus occurred in 20%-29% of cilofexor versus 15% of placebo-treated patients. In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.

Sections du résumé

BACKGROUND AND AIMS

Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease.

APPROACH AND RESULTS

In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 mg, cilofexor 30 mg, or firsocostat 20 mg, alone or in two-drug combinations, once-daily for 48 weeks. The primary endpoint was a ≥1-stage improvement in fibrosis without worsening of NASH between baseline and 48 weeks based on central pathologist review. Exploratory endpoints included changes in NAFLD Activity Score (NAS), liver histology assessed using a machine learning (ML) approach, liver biochemistry, and noninvasive markers. The majority had cirrhosis (56%) and NAS ≥5 (83%). The primary endpoint was achieved in 11% of placebo-treated patients versus cilofexor/firsocostat (21%; P = 0.17), cilofexor/selonsertib (19%; P = 0.26), firsocostat/selonsertib (15%; P = 0.62), firsocostat (12%; P = 0.94), and cilofexor (12%; P = 0.96). Changes in hepatic collagen by morphometry were not significant, but cilofexor/firsocostat led to a significant decrease in ML NASH CRN fibrosis score (P = 0.040) and a shift in biopsy area from F3-F4 to ≤F2 fibrosis patterns. Compared to placebo, significantly higher proportions of cilofexor/firsocostat patients had a ≥2-point NAS reduction; reductions in steatosis, lobular inflammation, and ballooning; and significant improvements in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, bile acids, cytokeratin-18, insulin, estimated glomerular filtration rate, ELF score, and liver stiffness by transient elastography (all P ≤ 0.05). Pruritus occurred in 20%-29% of cilofexor versus 15% of placebo-treated patients.

CONCLUSIONS

In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.

Identifiants

DOI: 10.1002/hep.31622 PMID: 33169409

pubmed: 33169409

doi: 10.1002/hep.31622

pii: 01515467-202102000-00014

doi:

Substances chimiques

Azetidines 0

Benzamides 0

Biomarkers 0

Imidazoles 0

Isobutyrates 0

Isonicotinic Acids 0

Oxazoles 0

Pyridines 0

Pyrimidines 0

selonsertib NS3988A2TC

firsocostat XE10NJQ95M

cilofexor YUN2306954

Banques de données

ClinicalTrials.gov

['NCT03449446']

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

625-643

Subventions

Organisme : NIDDK NIH HHS

ID : P30 DK120515

Pays : United States

Informations de copyright

Références

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84.

Loomba R, Chalasani N. The hierarchical model of NAFLD: prognostic significance of histologic features in NASH. Gastroenterology 2015;149:278‐281.

Angulo P, Kleiner DE, Dam‐Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389‐397.e10.

Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 2019;70:1913‐1927.

Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non‐alcoholic fatty liver disease. Gut 2017;66:180‐190.

Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 2020;72:58‐71.

Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217‐225.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non‐alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo‐controlled phase 3 trial. Lancet 2019;394:2184‐2196.

Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJ, Jr. et al. Acetyl‐coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double‐blind, crossover study. Hepatology 2017;66:324‐334.

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, et al. GS‐0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 2018;155:1463‐1473.e6.

Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73:26‐39.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313‐1321.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero‐Gomez M, Okanoue T, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 2019;70:1521‐1530.

Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018;155:1140‐1153.

Pokkalla H, Pethia K, Glass B, Kerner JK, Gindin Y, Han L, et al. Machine learning models accurately interpret liver histology in patients with nonalcoholic steatohepatitis. Hepatology 2019;70(Suppl.):121A‐122A.

Younossi ZM, Pokkalla H, Pethia K, Glass B, Kerner JK, Gindin Y, et al. Machine learning fibrosis models based on liver histology images accurately characterize the heterogeneity of cirrhosis due to nonalcoholic steatohepatitis (NASH). Hepatology 2019;70(Suppl.):1033A.

Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, et al. Acetyl‐CoA carboxylase inhibitor GS‐0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2018;16:1983‐1991.e3.

Sanyal A, Harrison S, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell SH, et al. Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. J Hepatol 2017;66:S1‐S32.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, et al. Insulin sensitizer MSDC‐0602K in non‐alcoholic steatohepatitis: a randomized, double‐blind, placebo‐controlled phase IIb study. J Hepatol 2020;72:613‐626.

Bates J, Hollenback D, Zagorska A, Budas G, Liles J, Liu H, et al. Combination of an FXR agonist and an ACC inhibitor increases anti‐fibrotic efficacy in rodent models of NASH. J Hepatol 2018;68:S395‐S396.

Papazyan R, Liu X, Liu J, Dong B, Plummer EM, Lewis RD, et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human‐like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res 2018;59:982‐993.

Neuschwander‐Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial. Lancet 2015;385:956‐965.

Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014;59:1393‐1405.

Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular reaction in liver diseases: pathological mechanisms and translational significances. Hepatology 2019;69:420‐430.

Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab 2017;26:394‐406.e396.

Goedeke L, Bates J, Vatner DF, Perry RJ, Wang T, Ramirez R, et al. Acetyl‐CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology 2018;68:2197‐2211.

Lawitz E, Herring R, Jr., Younes ZH, Gane E, Ruane P, Schall RA, et al. Proof of concept study of an apoptosis‐signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl‐CoA carboxylase inhibitor (GS‐0976) or a farnesoid X receptor agonist (GS‐9674) in NASH. J Hepatol 2018;68:S37‐S64.